E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Bones and nerves physological processes [G11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000452 |
E.1.2 | Term | Achondroplasia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to collect consistent baseline growth measurements on pediatric subjects being considered for subsequent enrollment in other future studies sponsored by BioMarin. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Individuals eligible to participate in this study must meet all of the following criteria: 1. Parent(s) or guardian(s) willing and able to provide signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, willing and able to provide written assent (as needed) after the nature of the study has been explained and prior to performance of any research-related procedure. 2. Birth to ≤ 17 years of age at study entry. 3. Have ACH, documented by clinical diagnosis 4. Are ambulatory and able to stand without assistance (not applicable for children who are younger than 5 years of age and less than 104 cm in length) 5. Are willing and able to perform all study procedures as physically possible |
|
E.4 | Principal exclusion criteria |
Individuals who meet any of the following exclusion criteria are not eligible to participate in the study: 1. Have hypochondroplasia or short stature condition other than ACH (e.g., trisomy 21, pseudoachondroplasia) 2. Have any of the following disorders: o Hypothyroidism o Insulin-requiring diabetes mellitus o Autoimmune inflammatory disease (including celiac disease, lupus (SLE), juvenile dermatomyositis, scleroderma, and others) o Inflammatory bowel disease o Autonomic neuropathy 3. Have an unstable clinical condition likely to lead to intervention during the course ofthe study, including progressive cervical medullary compression 4. Growth plates have fused 5. Have a history of any of the following: o Renal insufficiency o Anemia 6. Have a history of cardiac or vascular disease, including the following: o Cardiac dysfunction o Hypertrophic cardiomyopathy o Congenital heart disease o Cerebrovascular disease, aortic insufficiency o Clinically significant atrial or ventricular arrhythmias 7. Current treatment with antihypertensive medications, ACE inhibitors, angiotensin IIreceptor blockers, diuretics, beta-blockers, calciumchannel blockers, cardiacglycosides, systemic anticholinergic agents, any medication that may impair orenhance compensatory tachycardia, drugs known to alter renal function that isexpected to continue for the duration of the study 8. Have been treated with growth hormone, insulin-like growth factor 1 (IGF-1), oranabolic steroids in the previous 6 months or long-term treatment (> 3 months) at anytime 9. Have had regular long-term treatment (> 1 month) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable) in the previous 12 months 10. Concomitant medication that prolongs the QT/QTc interval within 14 days or5 half-lives, whichever is longer, before the Screening visit 11. Have used any other investigational product or investigational medical device for the treatment of ACH or short stature 12. Planned or expected bone-related surgery (ie. surgery involving disruption of bone cortex), during the study period. Subjects with previous bone-related surgery may enroll if surgery occurred at least 12 months prior to the study and healing is complete without sequelae. 13. Planned or expected to have limb-lengthening surgery during the study period.Subjects with previous limb- lengthening surgery may enroll if surgery occurred at least 18 months prior to the study and healing is complete without sequelae. 14. Have any condition that, in the view of the Investigator, places the subject at high risk of poor compliance with the visit schedule or of not completing the study. 15. Concurrent disease or condition that, in the view of the Investigator, would interferewith study participation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Growth measurements at baseline and then subsequently at 3-month intervals |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Study completion (enrollment in another study), discontinuation of participation, or termination of the study |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Clinical Assessment Study |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Japan |
Turkey |
United States |
France |
Germany |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 12 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |